Canaccord cuts Artivion stock price target on revenue outlook

Artivion reported Q3 revenue of $123.8 million, up 9% year over year, and adjusted EBITDA of $22.5 million and EPS of $0.08, each above analyst estimates. It tightened fiscal 2026 revenue guidance to $484–$492 million and adjusted EBITDA guidance to $93–$98 million, with both midpoints unchanged; Canaccord cut its price target to $30 from $40 while retaining a Buy rating. Management flagged about $10 million of PERCLOT revenue lost starting in 2027, and the article notes the stock declined during the regular session despite the earnings beat.

Analysis

The key issue is the timing mismatch between a known product-revenue roll-off and a later growth option. PERCLOT’s 2027 loss pressures the bridge to NEXUS, whose commercial contribution is not expected until cases build during 2027; meanwhile, slower core stent-graft growth leaves less room to absorb the gap. The EBITDA-growth haircut exceeding the revenue-growth haircut is a warning that mix and operating leverage may amplify the transition, not just trim the top line. AMDS adoption is a potential offset, but sequential implant progress is not yet proof of scalable economics: the starter-set upfront cost may slow surgeon and account conversion, so track repeat utilization and reorder rates rather than launch activity alone.

Near term, the earnings beat is weaker evidence than the stock reaction and downward estimate revisions: investors appear focused on margin quality and cash conversion. Over 1–3 months, monitor quarterly free cash flow, core stent-graft growth, and any further estimate cuts. Over 6–18 months, NEXUS launch execution and AMDS utilization determine whether the portfolio can replace the lost growth. The contrarian case is that the PERCLOT reset is now explicit and a successful NEXUS ramp could restore growth; however, the wide analyst target range is not evidence that the transition risk is resolved. Thesis weakens if free cash flow improves alongside stable core growth and repeat AMDS utilization; it strengthens if guidance or estimates fall again, or launch milestones slip.

Key Decisions for Investors

• Underweight or avoid adding to AORT on the headline beat; the 2027 replacement-product timing and cash-conversion questions are not resolved by a modest quarterly surprise. Reassess after the next report rather than setting an unsupported price target.
• For existing exposure, consider a relative-value hedge: reduce AORT risk against a diversified medical-device position. This limits broad sector exposure but leaves substantial company-specific basis risk; size accordingly.
• Set alerts for quarterly free cash flow, core stent-graft growth, AMDS repeat utilization/reorders, and NEXUS launch milestones. Upgrade the thesis only if these show durable conversion and the PERCLOT gap is being offset; further estimate cuts or launch slippage would falsify the stabilization case.